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Abstract
Human cytomegalovirus (HCMV) is a widely prevalent human herpesvirus, which, after primary infection, persists in the host
for life. In healthy individuals, the virus is well controlled by the HCMV-specific T cell response. A key feature of this
persistence, in the face of a normally robust host immune response, is the establishment of viral latency. In contrast to lytic
infection, which is characterised by extensive viral gene expression and virus production, long-term latency in cells of the
myeloid lineage is characterised by highly restricted expression of viral genes, including UL138 and LUNA. Here we report
that both UL138 and LUNA-specific T cells were detectable directly ex vivo in healthy HCMV seropositive subjects and that
this response is principally CD4+ T cell mediated. These UL138-specific CD4+ T cells are able to mediate MHC class II
restricted cytotoxicity and, importantly, show IFNc effector function in the context of both lytic and latent infection.
Furthermore, in contrast to CD4+ T cells specific to antigens expressed solely during lytic infection, both the UL138 and
LUNA-specific CD4+ T cell responses included CD4+ T cells that secreted the immunosuppressive cytokine cIL-10. We also
show that cIL-10 expressing CD4+ T-cells are directed against latently expressed US28 and UL111A. Taken together, our data
show that latency-associated gene products of HCMV generate CD4+ T cell responses in vivo, which are able to elicit effector
function in response to both lytic and latently infected cells. Importantly and in contrast to CD4+ T cell populations, which
recognise antigens solely expressed during lytic infection, include a subset of cells that secrete the immunosuppressive
cytokine cIL-10. This suggests that HCMV skews the T cell responses to latency-associated antigens to one that is overall
suppressive in order to sustain latent carriage in vivo.
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Introduction
Human cytomegalovirus (HCMV) is widely prevalent, with an
estimated 50–60% of the world population being seropositive [1].
Primary infection in the immunocompetent host is usually
asymptomatic and overt disease is seen almost exclusively in the
immunocompromised and immuno-naive host. For example,
placental transmission of HCMV is a leading infective cause of
congenital abnormalities [2]. Primary infection with HCMV
induces a robust innate and adaptive immune response, which
includes a substantial CD4+ and CD8+ T cell response [2–4],
which is essential for the control of HCMV disease [5–8].
However, despite this extensive immune response, HCMV is not
cleared but persists for the lifetime of the host due, at least in part,
to the establishment of viral latency in certain cell types, where the
viral genome is carried in the absence of the production of
infectious viral progeny [9,10].
One defined site of latency of HCMV in vivo is in cells of the
myeloid lineage, including CD34+ haematopoietic progenitor cells
of the bone marrow [11–14]. Furthermore, differentiation of
CD34+ cells to terminally differentiated cells of the myeloid
lineage, such as macrophages or dendritic cells, results in
reactivation of infectious virus [12,15–17]. Despite probable
frequent occurrences of reactivation events in vivo, these events
are likely asymptomatic due to an active and robust immune
response. In contrast, in an immunocompromised setting, the lack
of a functional T cell response results in uncontrolled virus
replication, which can occur during primary infection, super-
infection or reactivation [2,18,19] and result in significant clinical
disease [2,18].
The viral proteins recognised by HCMV-specific T cells during
lytic infection have been extensively investigated. The immediate
early proteins IE1 and IE2 (UL123 and UL122, respectively), as
well as the tegument protein pp65 (UL83), were all recognized by
both CD4+ and CD8+ T cells in the majority of individuals,
regardless of HLA type. In contrast, although T cells specific for
glycoprotein B (UL55) are also frequently generated they are
predominantly CD4+ T cells [20–23]. Using synthetic peptide
libraries spanning the entire predicted HCMV proteome, a
comprehensive analysis of the breadth and frequency of the
CD4+ and CD8+ T cell response to HCMV has been carried out.
These data showed that, in a large cohort of healthy seropositive
donors with a diverse range of HLA types, a CD4+ or CD8+ T cell
response was detectable to over 150 viral ORFs which included
both structural and non-structural proteins expressed during all
phases of lytic infection [20,21]. Furthermore, they also observed
that in any given donor CD4+ and CD8+ T cell responses
recognised a median of 8 ORFs and 12 ORFs, respectively,
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suggesting that a large repertoire of HCMV ORFs were
recognised by the immune response.
In contrast to lytic infection, during which pivotal genes such as
the viral immediate early (IE) genes drive expression of early and
late genes such as pp65 and gB, viral gene expression during
latency is highly restricted. In the absence of IE gene expression,
an accepted characteristic of latent infection, only a handful of
viral genes have been shown to be expressed during natural and
experimental models of latent infection [24–31]. These include:
UL138, LUNA (latency-associated unidentified nuclear antigen)
an antisense transcript to the UL81–82 region, UL111A (vIL-10) a
viral homologue of cellular IL-10 (cIL-10) and US28, a chemokine
receptor homologue [28,32].
Although the functional role of these latency-associated genes
during latency is far from clear, we hypothesised that the robust
and antigenically broad T cell immune response elicited by
HCMV would likely include responses to these latency-associated
antigens, since they are expressed during lytic infection also.
Consistent with this, recent evidence has suggested a limited CD8+
T cell response to UL138 is present in healthy individuals [33].
However, if this was generally the case it would raise the question
as to why such responses do not expose the latently infected cell to
immune recognition and eventual clearance. Clearly, understand-
ing this is of crucial importance to understanding the mechanism
of latent carriage.
In this study we have measured and characterised UL138 and
LUNA specific T cell responses in a cohort of healthy HCMV
seropositive donors. Here we show, that they elicit predominantly
CD4+ Th1 type responses, characterised by IFNc production.
Additionally, we observe that UL138 specific CD4+ T cells
mediated MHC class II restricted cytotoxicity. These CD4+ T cells
are able to recognize antigen both in lytically infected dendritic
cells and, importantly, they also recognize latently infected
monocytes. Intriguingly, a proportion of the UL138 and LUNA
specific CD4+ T cells also secreted the immunomodulatory
cytokines cIL10 and transforming growth factor b (TGF-b).
Importantly, additional analysis of two other latency-associated
proteins (US28 and vIL-10), showed that these antigens also
generated CD4+ T cell responses which again were able to secrete
cIL-10. To our knowledge this is the first description of HCMV
specific cIL-10 producing CD4+ T cells in normal healthy HCMV
seropositive individuals. We hypothesise that this T cell response,
which includes potentially suppressive T cells specific to latent
antigens, may function to assist in the lifelong carriage and
maintenance of the latent reservoir of infection by preventing
efficient Th1 T cell recognition of latently infected cells.
Results
UL138 and LUNA specific T cells are generated by HCMV
seropositive individuals
In order to determine whether T cell responses to UL138 or
LUNA proteins could be detected, IFNc specific ELISPOT assays
were performed on whole freshly isolated peripheral blood
mononuclear cells (PBMC) or PBMC depleted of either CD4+
or CD8+ T cells from both HCMV seropositive (n = 17) and
seronegative donors (n = 6). Isolated cells were stimulated with
overlapping pools of peptides spanning either the UL138 or
LUNA predicted open reading frames and T cell recognition was
determined by IFNc production. In parallel, we performed a
concomitant analysis of the response to pools of peptides spanning
the HCMV ORFs IE1/2 (UL123 and UL122), pp65 (UL83) and
gB (UL55), which are well defined CD4+ and CD8+ T cell antigens
in HCMV seropositive individuals (Table 1).
As expected, substantial spot forming units (SFU) (SFU/106
.100) CD4+ and CD8+ T cell responses to pp65 (CD8+ T cells
15/17 donors and CD4+ T cells 12/17 donors), IE (CD8+ T cells
17/17 and CD4+ T cells 11/17 donors) and gB (CD8+ T cells 3/
17 and CD4+ T cells 12/17 donors) were readily detected in the
HCMV seropositive, but not seronegative donors.
Interestingly, T cell responses to UL138 and LUNA were also
detected in many of the donors tested with responses greater than
100 SFU/106 cells to UL138 in 5/17 donors (range 120–
1295 SFU/106 cells) and to LUNA in 8/17 donors (range 100–
446 SFU/106 cells) seropositive donors tested. Furthermore,
responses .100 SFU/106 cells were mediated exclusively by
CD4+ T cells in all the UL138 and LUNA reactive donors
(Table 1); none of the seronegative donors tested made responses
(data not shown).
We confirmed that all donor PBMC and CD4/CD8 –depleted
PBMCs tested retained IFNc producing effector function following
polyclonal stimulation using phytohaemagglutinin (PHA) (data not
shown). Taken together, these results clearly show that both
UL138 and LUNA generate a CD4+ T cell response and,
furthermore, the frequency of the response was in the lower to
middle range compared to CD4+ T cell responses to gB (Table 1).
In order to expand any UL138 specific T cells that were below the
detection limit of the ex-vivo ELISPOT assays purified CD8+ T
cells from three different donors were stimulated with the UL138
peptide pool and cultured for 12 days. These cultures were then
retested for UL138 specific responses by ELISPOT assays and
were negative in all cases (data not shown).
In order to confirm the frequencies of these CD4+ T cell
responses as well as determine more precisely the epitope
specificity, individual 15 amino acid overlapping peptides that
composed the UL138 and LUNA ORF pools were tested for T cell
reactivity against each donor. All 17 HCMV seropositive donors
were re-tested using the individual peptides from each ORF,
irrespective of whether they had a detectable response to UL138
or LUNA ORF pools in the initial screen.
The results show that no additional UL138 or LUNA IFNc
secreting T cell responses were detected by stimulation with the
Author Summary
Human cytomegalovirus (HCMV) is a widely prevalent
virus, which is normally carried without clinical symptoms,
but often causes severe clinical disease in individuals with
compromised immune responses. In healthy HCMV carri-
ers, the immune response to HCMV is robust and includes
large numbers of virus-specific T-cells that control viral
replication during active infection. Despite this prodigious
immune response, HCMV is never cleared after primary
infection but persists in the host for life: a key feature of
persistence is the ability of the virus to establish a type of
viral quiescence, termed latency. Although much is known
about T-cell responses to viral proteins expressed solely
during lytic infection, the interplay between the T-cell
response and latent HCMV is not well understood. Here we
report the first comprehensive characterisation of the T-
cell response to latent HCMV and show that it is composed
principally of CD4+ T-cells, which are specific for viral
proteins expressed during latency, and are able to detect
latent virus in vitro. We further show that these CD4+ T-cell
responses to latency-associated viral gene products
include T-cells that secrete cIL-10, an immunosuppressive
cytokine, which may function to suppress antiviral immune
responses and thereby maintain lifelong carriage of the
latent virus.
HCMV Latency-Associated Proteins and CD4+ T Cells
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individual peptides. All five donors previously shown to elicit a
CD4+ T cell responses to the UL138 ORF pool were restricted to
an immunogenic 15mer peptide or clusters of overlapping peptides
(Figure 1) including 3 donors (CMV300, 301, and 305) who
elicited high level IFNc production to the same 15mer peptide;
UL138 peptide 2 (LNVGLPIIGVMLVLI). Similarly, six of the
seven donors with a detectable LUNA specific T cell response
were mapped to either a 15mer peptide or alternatively to a
clusters of overlapping 15mer peptides (Figure 2). Again 3 donors
(CMV300, 302 and 317) showed IFNc+ T cell responses to the
same 15mer peptide, LUNA peptide 18 (RLILSGLPGVRVQNP).
UL138 and LUNA specific CD4+ T cell lines recognise lytic
HCMV infection of monocyte derived dendritic cells
UL138 and LUNA specific T cells are clearly generated in
response to HCMV infection and can be re-stimulated with
synthetic peptides. Consequently, we next addressed whether
UL138 and LUNA specific CD4+ T cells could be activated in
response to cells lytically infected with HCMV. CD4+ T cell lines
specific for UL138, LUNA as well as gB and IE were incubated
with either HCMV infected autologous monocyte derived
dendritic cells (moDC) or mock infected cells (Phenotypic analysis
of moDC shown in Figure S1). Following infection with HCMV,
approximately 10% of moDC cells were IE positive (Figure 3A).
Lack of availability of antibodies against UL138 and LUNA meant
an RT-PCR analysis was performed instead. Using this approach
we confirmed the expression of IE, UL138 and LUNA mRNAs
expression in lytically infected moDCs (Figure 3B). As expected, all
samples were positive for GAPDH and mock-infected moDCs
expressed no viral transcripts.
The results clearly show that both the UL138 and LUNA
specific T cells from donor CMV300 were activated following
stimulation with lytically infected moDC (Figure 3C). As expected,
gB and IE specific CD4+ T cells were also stimulated by virus
infected cells (Figure 3C). Consistent with specificity, all CD4+ T
cell lines were activated by the relevant gB, IE, UL138 and LUNA
peptide pulsed moDC. In contrast, no IFNc was detected
following stimulation with uninfected/peptide untreated moDC.
Similarly, CD4+ T cells specific for UL138 from a second donor
(CMV305) were tested for recognition of HCMV infected
autologous moDC. Again, we observed activation of all three
specificities in this donors’ CD4+ T cells (Figure S2). Furthermore,
repetition of the analyses on independent occasions confirmed
that, from both donors, latent specific T cells were activated by
lytically infected moDC (data not shown).
UL138 specific CD4+ T cells recognise and secrete IFNc in
response to latently infected monocytes
The previous experiments clearly demonstrated that HCMV
lytic infection of MHC Class II positive dendritic cells lead to
antigen presentation of both UL138 and LUNA peptides and
subsequent CD4+ T cell recognition. An important question was
whether these T cells could also be activated by latently infected
autologous monocytes. In order to determine if UL138 specific
CD4+ T cells could recognize latently infected cells, autologous
monocytes were prepared and latently infected with HCMV strain
TB40e for 10 days. The establishment of latency was confirmed by
RT-PCR analysis; latently infected monocytes were shown to
express the UL138 latent transcript with an absence of IE mRNA
expression (Figure 4A). Mock-infected monocytes did not express
UL138, while both mock and latently infected cells were GAPDH
positive.
UL138 and gB specific CD4+ T cells from donor CMV305 were
generated as previously described and co-incubated with autolo-
Table 1. Summary of HCMV specific IFNc secreting T cell response.
Donor pp65 IE gB UL138 LUNA
PBMC CD4 CD8 PBMC CD4 CD8 PBMC CD4 CD8 PBMC CD4 CD8 PBMC CD4 CD8
300 2500 720 2500 2448 1226 2500 2500 2500 94 524 1295 5 360 195 0
301 1800 825 2500 2500 2500 2146 2500 1360 24 120 168 8 138 125 15
302 2500 624 2500 2500 1284 2500 1682 1842 0 15 20 20 180 100 24
303 565 200 840 682 648 702 1342 1120 0 0 0 0 0 0 0
304 1640 0 1840 1080 42 1246 80 64 0 0 4 8 120 104 24
305 556 256 0 2328 2024 1462 2500 2500 642 656 1161 2 32 11 14
306 120 0 0 240 0 182 1340 1284 0 20 5 5 60 16 4
307 400 0 542 1650 4 1280 0 0 0 0 0 0 0 0 0
308 410 665 295 1274 24 1426 440 526 0 20 0 10 240 132 32
309 1240 0 874 1862 60 1642 148 206 0 0 4 4 0 4 4
312 642 128 536 2500 2242 2500 78 24 0 20 8 4 0 0 4
314 648 0 438 750 0 422 42 86 0 0 0 0 137 148 0
315 2236 246 2214 2026 466 2500 642 588 226 0 0 0 0 0 0
316 2248 2500 2500 2500 2500 1240 2500 2500 680 680 520 12 460 270 44
317 468 324 120 2500 642 2238 2500 2500 0 227 120 4 426 446 0
318 824 128 642 2500 804 2500 0 0 0 24 0 4 62 8 4
319 628 94 680 2242 1600 2208 1862 2234 0 0 12 8 0 8 4
Whole PBMC or PBMC depleted of either CD4+ or CD8+ T cells from 17 HCMV seropositive donors were stimulated with overlapping peptide pools spanning the HCMV
ORFs pp65, IE, gB, UL138 and LUNA. Cells were incubated for 48 hours and IFNc production was detected by ELISPOT. Post incubation IFNc spot forming units (SFU)
were enumerated and background levels of IFNc determined from a non-peptide stimulated control were subtracted from each value and converted into SFU/106 cells.
doi:10.1371/journal.ppat.1003635.t001
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gous latently or mock infected monocytes in IFNc ELISPOT
assays. As expected, no gB specific CD4+ T cell response against
HCMV latently infected monocytes was detected. In contrast, gB
specific CD4+ T cells clearly produced IFNc if the mock or latently
infected monocytes had been pulsed with gB peptide (Figure 4B).
These results are consistent with a lack of gB expression during
latent infection of monocytes but confirm that failure to detect gB
is not due to a defect in antigen presentation to gB-specific CD4+
T cells by autologous monocytes.
Interestingly, in contrast to our observations with gB, our results
show that UL138 specific CD4+ T cells produce IFNc in response
to incubation with latently infected monocytes (Figure 4C) as well
as when cells were pulsed with UL138 peptide. Identical analyses
were also performed using donor CMV300, which confirmed the
recognition of latently infected monocytes by CD4+ T cells specific
to UL138 (Figure S3). Further validation was achieved with
subsequent analyses of T cells and monocytes derived from donors
CMV300 and CMV305 which, again, confirmed that UL138
specific T cells recognized HCMV latently infected monocytes
(data not shown). To date, we have not been able to demonstrate if
LUNA protein expression in latently infected cells can be
recognised by LUNA specific T cells. Whether this is experimental
failure or intrinsic to LUNA remains an open question and is
currently under investigation.
UL138 but not LUNA specific CD4+ T cells mediate MHC
Class II restricted cytotoxicity
Classically, CD4+ T cells are considered helper T cells, exerting
effector functions by cytokine secretion in vivo. Indeed, it is well
established that T cell mediated cytotoxicity effector function is
associated with CD8+ T cell recognition of antigen presented by
MHC Class I. However, recent studies suggest that CD4+ T cells
may play a more direct role in viral infection. Pertinent to this
study, it has been shown in the context of HCMV infection that
Th1 type gB specific CD4
+ T cells that secrete IFNc and TNFa
have also been shown to be able to mediate MHC class II
restricted cytotoxicity [21,34–36].
Consequently, since both the UL138 and LUNA specific CD4+
T cell response is also characterised by IFNc production, we next
asked if these CD4+ T cells also have cytotoxic effector cell
function. To do this, UL138 specific CD4+ T cell lines from
donors CMV300 and CMV305 as well LUNA specific CD4+ T
cell lines from CMV300 were expanded in vitro for two weeks and
then tested for MHC Class II restricted cytotoxicity in vitro using
chromium release assays. Again gB specific CD4+ T cells were
used as a positive control.
Consistent with previously published findings [34,35] gB specific
CD4+ T cells mediated cytotoxicity (Figure 5A). Furthermore, our
results now show that UL138 specific CD4+ T cells are also able to
mediate cytotoxicity (Figure 5B). In contrast, LUNA specific CD4+
T cells were not cytotoxic at any E:T ratio examined (range 10:1–
80:1) (Figure 5C), although importantly, the LUNA specific T cells
remained antigen reactive by IFNc specific ELISPOT assays
(Figure 5D).
UL138 and LUNA specific CD4+ T cells include both IFNc
and cIL-10 producing CD4+ T cells
The CD4+ T cell response is potentially composed of multiple
subsets of CD4+ T cells with distinct functions and characteristic
cytokines they produce. The HCMV specific CD4+ T cell
response is characterised as being almost exclusively Th1 mediated,
secreting IFNc in response to lytic antigens such as gB and IE.
However, it is interesting to note that parallels with other herpes
Figure 1. Mapping of UL138 specific T cell responses to
individual 15 amino acid peptides. PBMC from 17 HCMV
seropositive donors were stimulated with 32 individual 15 amino acid
overlapping peptides covering UL138 ORF in a 48 hour IFNc ELISPOT
assay. Post incubation IFNc spot forming units (SFU) were enumerated
and the value from an unstimulated control was subtracted before
conversion to SFU/106 cells. Data shown is from the 5 donors who
made T cell responses to the complete UL138 ORF peptide pool
(Table 1).
doi:10.1371/journal.ppat.1003635.g001
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viruses may be apparent: CD4+ T cells specific for a latent protein
of EBV (LMP1) are able to secrete the immunosuppressive
cytokine cIL-10 which is thought to play a role in evading immune
responses during latent infection and maintenance of EBV latency
[37–39]. Consequently, we analysed the cytokine profile of UL138
and LUNA specific CD4+ T cells following antigen stimulation
and compared this to the well characterized response made by gB
specific CD4+ T cells using a multi-analyte Th1/Th2 cytokine
assay which measured 11 cytokines simultaneously.
CD4+ T cells specific to the lytic protein gB induced high levels
of the classic Th1 type cytokines IFNc, TNFa and IL2 as expected
(Figure 6A) [34,35]. Both donor CMV300 and CMV 305
responded to the same UL138 peptide (LNVGLPIIGVMLVLI).
Interestingly, stimulation of UL138 specific CD4+ T cell lines
(from donors CMV 300 and CMV305) resulted in a cytokine
secretion profile with increased heterogeneity when compared to
that observed from gB specific T cells. Specifically we detected the
secretion of IFNc, TNFa, IL-2, IFNb, IL-6, IL-8 and low levels of
IL-4 and IL-5 (Figure 6A). Interestingly, UL138 specific CD4+ T
cells also produced high levels of the immunomodulatory cytokine
cIL-10 in both these donors – an event not seen in response to gB
peptide stimulation. Similarly, stimulation of donor CMV 300s’
LUNA specific CD4+ T cells also produced a heterogeneous range
of cytokines including, pertinently, cIL-10 (Figure 6A).
The detection of cIL-10 producing T cells that appeared
restricted to the recognition of latently expressed HCMV antigens
was intriguing. CD4+ T cell production of cIL-10 has been
described in a subset of helper T cells associated with immune
regulatory functions described as T regulatory cells (Treg). Treg are
potent modulators of immune responses and exert their effects at
least partly via the production of immunomodulatory cytokines,
TGFb and cIL-10. Consistent with this phenotype, both UL138
and LUNA specific CD4+ T cells (from donor CMV300) produced
TGFb upon peptide stimulation, while gB specific CD4+ T cells
from the same donor did not (Figure 6B). A parallel analysis for
IFNy and cIL-10 on the T cell lines was performed to assess the
frequency of IFNc and cIL-10 producing cells in the line. As
previously, gB, UL138 and LUNA specific CD4+ T cells all
produced IFNc upon antigenic stimulation (Figure 6C). Further-
more, UL138 and LUNA, but not gB-specific, CD4+ T cells were
again shown to secrete cIL-10 (Figure 6D). However, the
ELISPOT assays also indicated that the frequency of cIL-10
producing UL138 and LUNA specific T cells was less than the
IFNc producing frequency.
What was not clear from these initial analyses was whether the
UL138 specific T cell response we observed was composed of
polyfunctional T cells which secrete both pro-inflammatory and
immunomodulatory cytokines, or whether the IFNc and cIL-10
producing T cells were actually separate populations.
To address this, PBMC were stimulated with peptide and then
assayed for the production and co-expression of IFNc and cIL-10
from CD4+ T cells by intracellular cytokine staining and flow
cytometry. These data show that the stimulation of PBMC from
both donors with UL138 peptide resulted in the generation of
Figure 2. Mapping of LUNA specific T cell responses to
individual 15 amino acid peptides. PBMC from 17 HCMV
seropositive donors were stimulated with 20 individual 15amino acid
overlapping peptides covering the LUNA peptide pool in a 48 hour
IFNc ELISPOT assay. Post incubation IFNc spot forming units (SFU) were
enumerated and the value from an unstimulated control was
subtracted before conversion to SFU/106 cells. Data shown is from
the 6 donors who made T cell responses to the whole LUNA ORF
peptide pool (Table 1).
doi:10.1371/journal.ppat.1003635.g002
HCMV Latency-Associated Proteins and CD4+ T Cells
PLOS Pathogens | www.plospathogens.org 5 October 2013 | Volume 9 | Issue 10 | e1003635
IFNc and cIL-10 producing cells, however, the UL138 specific
cells were composed of separate populations of CD4+ T cells that
secreted either IFNc or cIL-10 and not both (Figure S4A). These
data were recapitulated in PBMC from donor CMV300 that
exhibited a LUNA specific response composed of separate IFNc
and cIL-10 producing CD4+ T cells. A further donor, CMV317,
with a known response to both UL138 and LUNA (Table 1,
Figure 1 and Figure 2) also showed that both UL138 and LUNA
specific CD4+ T cells were again composed of separate popula-
tions of IFNc and cIL-10 producing CD4+ T cells. Taken together
these data show that different subsets of T cells within the CD4+ T
cell response can be detected and characterised by their cytokine
expression profile (summarised in Figure S4B).
Finally, CD4+ T cell lines specific to gB and UL138 were also
generated from donor CMV305 and, 14 days post in vitro
expansion, the production of IFNc and cIL-10 examined in a
similar manner. Consistent with our ex vivo analyses, the expanded
gB specific CD4+ T cells were again composed solely of IFNc
producing cells whereas UL138 specific CD4+ T cells were again
composed of separate populations that produced either IFNc or
cIL-10 (Figure S4C).
Supernatant from UL138 stimulated CD4+ T cells inhibit
CD4+ T cell proliferation
We reasoned that the observation that UL138 specific CD4+ T
cells, but not gB specific CD4+ T cells, secreted the immunomod-
ulatory cytokines cIL-10 and TGFb upon stimulation with cognate
peptide could potentially result in suppression of the host T cell
response. If this was the case then the supernatants from UL138
specific CD4+ T cells could impact upon the proliferative response
of polyclonally activated CD4+ T cells. PBMC from three donors
were polyclonally stimulated with anti-CD3/CD28 beads in the
presence of supernatant from T cells stimulated for 48 hours with
either UL138 or gB specific peptides or media control. Prolifer-
ation of CD4+ T cells was measured by dye dilution using flow
cytometry (Figure 7). Consistent with the prediction that the
secretion of cIL-10 and TGF-b was indicative of Treg phenotype
we observed that the supernatant from cells stimulated with
UL138 (but not gB) peptide, suppressed CD4+ T cell proliferation
(p,0.01; n = 3) (Figures 7B and C). Supernatant from cells
stimulated with UL138 peptide were treated with neutralizing
antibodies specific for cIL-10 and TGFb. The results show that
proliferation was partially restored by either neutralizing antibody
and in combination proliferation was fully restored to the level of
the control (Figure 7D).
CD4+ T cell lines specific for UL138 and LUNA, but not gB
include a subset of cells expressing phenotypic markers
of Treg
The production of the immunomodulatory cytokines cIL-10
and TGFb, by CD4+ T cells has been shown to be associated
with the function of a subset of immunosuppressive CD4+ T
cells termed regulatory T cells (Treg) [40]. Indeed, it has been
shown previously that the EBV specific CD4+ T cell response
includes a Treg component specific to a viral gene product
expressed during EBV latency [37]. Furthermore, it has also
been shown that HCMV can induce the expansion of virus
Figure 3. UL138 and LUNA specific CD4+ T cells are stimulated by HCMV lytic infection of monocyte derived dendritic cells. Dendritic
cells were prepared from donor CMV300 and mock or lytically infected with HCMV strain TB40e at MOI 5. After 5 days lytic infection was confirmed by
IE expression using immunofluorescence (A) and RT-PCR (B). Autologous mock or TB40e infected dendritic cells were then co-incubated with in vitro
expanded antigen specific CD4+ T cells specific to gB, IE, UL138 or LUNA in IFNc ELISPOT assays in the presence or absence of cognate peptide (C).
Post incubation IFNc spot forming units (SFU/106) were enumerated and the back ground level of IFNc production for each antigen specificity
determined from the mock infected no peptide control (Red dotted line).
doi:10.1371/journal.ppat.1003635.g003
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specific CD4+ T cells that express phenotypic markers associ-
ated with Treg [41].
Thus our data so far was highly suggestive that the detection of
latent antigens was concomitant with the development of subset of T
cells with Treg phenotype. To address this definitively we next
examined whether the expanded CD4+ T cells specific to UL138,
LUNA or gB were populated, in part, with phenotypically defined
Treg cells – based on CD4
+ CD25hi FoxP3+ expression [42–46].
CD4+ T cell lines specific to UL138 (Figure 8A) and gB (Figure 8B)
were generated and on day 14 of the expansion protocol assessed for
stable expression of CD25. The data clearly showed that UL138 but
not gB specific CD4+ T cells expressed CD25 after 14 days in vitro
culture (p,0.01, n = 3) (Figure 8C). We further characterised these
cells by determining FoxP3 expression as an indicator of Treg cells.
Having established the staining conditions to identify CD4+CD25hi-
FoxP3+ T cells using whole PBMC (Figure 8D) the CD25, FoxP3
phenotype of CD4+ T cells specific to gB, LUNA and UL138, or gB
and UL138 from donors CMV300 or CMV305, respectively, were
determined (Figure 8E). The results clearly show that CD4+CD25hi
cells expressing FoxP3, were detected in in vitro T cell cultures of
UL138 and LUNA specific T cells, but not those specific for gB, in
both donors tested. These data showed that a subset of the cells
specific for UL138 and LUNA, but not gB, present in the expanded T
cell cultures, expressed phenotypic markers consistent with Treg cells.
Cytokine profile of UL138 and LUNA specific CD4+ T cells
stimulated directly ex vivo
Although unlikely, it was necessary to exclude the possibility that
the culture conditions to produce UL138 and LUNA-specific T cell
lines induced or favoured cIL-10 producing T cells in vitro. Thus, we
assayed for cIL-10 production from T cells isolated directly ex vivo
without prior in vitro expansion. In addition, this nature of this analysis
allowed us to assess if cIL-10 production by UL138 and LUNA
specific T cells was common in a larger panel of donors. Parallel
ELISPOT assays detecting IFNc, cIL-10, IL-4 and IL-17 were thus
performed on 13 HCMV seropositive donors using peptides derived
from both latent and lytic antigens. The ELISPOT assays for each
cytokine (IFNc, cIL-10, IL-4 and IL-17) were enumerated and the
cytokine frequencies were used to determine the percentage of each
individual cytokine to the total antigen specific response.
Having first confirmed that we could detect all four cytokines in
the PBMC from all 13 donors following stimulation with PHA
(Figure 9A) we next assayed the effect of specific peptides on cytokine
production. As we have demonstrated repeatedly, stimulation with
gB, IE, UL138 or LUNA elicited IFNc responses. IE stimulation was
dominated by IFNc responses while gB elicited predominantly IFNc
however, we note that we did detect a few donors having a small cIL-
10 response and 2 donors having a more substantial cIL-10
responding T cell population. In contrast, the cytokine responses to
both LUNA and UL138 were much more heterogeneous with most
donors producing both IFNc and cIL-10 and some donors having a
predominantly cIL-10 response (Figure 9B). Absolute values (SFU/
106 cells) for the total T cell response (IFNc, cIL-10, IL-4 and IL-17)
to each antigen are also shown (Figure S5).
T cells specific for two additional latency-associated gene
products, UL111A and US28, also include CD4+ T cells
that express both IFNc and cIL-10
Finally we expanded these analyses to test whether other viral
gene products expressed during latency were responsible for a
Figure 4. UL138 specific CD4+ T cells secrete IFNc in response
to latently infected monocytes. Monocytes were prepared from
donor CMV305 and mock infected or latently infected with TB40e for 10
days at MOI 5. Latent infection was then confirmed by RT-PCR (A).
Autologous mock or latently infected monocytes were then co-
incubated with in vitro expanded antigen specific CD4+ T cells specific
to gB (B) and UL138 (C) in IFNc ELISPOT assays in the presence or
absence of cognate peptide. Post incubation IFNc spot forming units
(SFU/106) were enumerated and the back ground level of IFNc
production for each antigen specificity determined from the mock
infected no peptide control (Red dotted line). Error bars are standard
error of the mean (n = 5). Statistical analysis were performed using the
students t test (* p,0.05;** p,0.01).
doi:10.1371/journal.ppat.1003635.g004
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similar T cell phenotype observed with UL138 and LUNA –
namely, UL111A (an HCMV homologue of cIL-10) and US28 (an
HCMV chemokine receptor homologue) [27–32,47–51]. We
stimulated the same 13 donors with overlapping ORF peptide
pools to UL111A and US28, and measured IFNc, cIL-10, IL-4
and IL-17 cytokine production in separate ELISPOT assays
(Figure 9B). Absolute values (SFU/106 cells) for the total T cell
response (IFNc, cIL-10, IL-4 and IL-17) to each antigen are also
shown (Figure S5). These results clearly show that donors did have
both UL111A and US28 specific T cells and, importantly, while
IFNc responses could be measured the dominant cytokine to these
antigens was cIL-10. Furthermore, we note that some donors also
had small IL-4 or IL-17 cytokine responses. Taken together these
data clearly show that there is a circulating population of CD4+ T
cells detectable directly ex vivo that recognise latently expressed
HCMV antigens and which have a phenotype consistent with the
production of the immunomodulatory cytokine cIL-10.
Discussion
The results we present here represent the first comprehensive
analysis of T cell responses to those viral proteins associated with
latent HCMV infection. In general, and in contrast to antigens
solely associated with virus lytic infection (such as IE, gB and
pp65), our results show that healthy seropositive donors have
robust T cell responses to all the latency-associated antigens we
analysed, which are dominated by CD4+ T cells. As expected,
these CD4+ T cells recognise cells lytically infected with HCMV
but, importantly, also recognise latently infected monocytes.
There have been few other analyses of T cell responses to
HCMV encoded ORFs associated with latent infection. In a total
proteome screen for HCMV-specific T cell responses undertaken
by Sylwester et al (2005) only one donor out of 33 was identified as
having a UL138-specific CD4+ and CD8+ T cell response whereas
LUNA was not included in their analysis [21]. Similarly, an
independent analysis of UL138 identified UL138-specific CD8+ T
cell responses, but only in individuals who expressed the HLA-
B3501 haplotype [33]. Our study also included four HCMV
seropositive donors who expressed HLA-B3501, but none of these
individuals had detectable CD8+ T cell responses to UL138 in our
hands. These differences could be due to the methods used to
detect antigen specific T cells - our studies used ELISPOT assays
to screen directly ex vivo, in contrast to an in vitro antigen
stimulation to induce T cell expansion and pre-enrichment prior
to detection of IFNc used in the previous study [33]. Also, in
contrast to Tey et al (2010), who reported an absence of CD4+ T
cell responses to either UL138 or LUNA, we observed robust
CD4+ T cell responses to these antigens in healthy donors. Again,
it is likely that experimental differences between the studies, such
as the size of the individual peptides, the use of the ELISPOT
assays versus intracellular cytokine detection and the duration of
the assay (48 hours v 6 hours restimulation) may account for these
discrepancies.
Consistent with the knowledge that UL138 and LUNA are also
expressed during lytic infection, our data clearly showed that
CD4+ T cells specific to these viral proteins were able to recognize
Figure 5. CD4+ T cells specific to UL138, but not LUNA can
mediate MHC class II restricted cytotoxicity. Antigen specific
CD4+ T cells specific to gB (A), UL138 (B) and LUNA (C) from donor
CMV300 were expanded in vitro and incubated with autologous LCL in
the presence or absence of cognate peptide at a range of effector to
target cell ratios (E:T) in 6 hour chromium release assays. Percent
specific lysis was calculated to determine cytotoxic effector potential of
the antigen specific T cells. Values .10% were deemed positive. Error
bars are standard error of the mean (n = 6). The LUNA specific T cell line
used in (C) was tested for specificity in IFNc ELISPOT assays (D). Error
bars represent standard error of the mean (n = 3). Statistical analysis was
performed using the students t test (** p,0.01).
doi:10.1371/journal.ppat.1003635.g005
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Figure 6. In vitro expanded UL138 and LUNA specific CD4+ T cells secrete IFNc and IL-10. CD4+ T cells from donors CMV300 and CMV305
specific to gB and UL138 were expanded in vitro, LUNA specific cells were also expanded from donor CMV300. Antigen specific CD4+ T cells were then
incubated with autologous LCL in the presence or absence of peptide and supernatants removed and assayed for 11 cytokines by multi-analyte
cytokine assays (A). Supernatants from the same experiment were also used in TGFb ELISA (B). gB, UL138 and LUNA specific CD4+ T cells were then
incubated with autologous irradiated PBMC in the presence and absence of peptide in ELISPOT assays detecting IFNc (C) and IL-10 (D) including the
mitogen PHA as a positive control. Error bars are standard error of the mean (n = 5).
doi:10.1371/journal.ppat.1003635.g006
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lytically infected moDCs. Furthermore, UL138 specific CD4+ T
cells expanded in vitro were also able to mediate cytotoxicity against
peptide-loaded autologous target cells. This recognition of lytically
infected DCs, and concomitant secretion of IFNc, occurred
despite the expression of those viral genes associated with lytic
infection that are known to modulate immune responses [3,52–
55]. However, this is not inconsistent with numerous studies which
have shown potent anti-viral CD4+ T cell responses to other
antigens such as gB and IE (expressed only during lytic infection)
in HCMV infected cells, despite expression of the known viral
immune-evasins [34,56].
Our observations that CD4+ T cells specific for UL138 could
also recognise latently infected cells and secrete IFNc leads to an
obvious conundrum: this ability of the host to recognise latently
infected cells carries the risk that the latently infected cells should
become targets for immune clearance. However, it is already
known that HCMV is able to modify the latently infected cell itself
in order to reduce T cell recognition and activation. During latent
infection expression of viral UL111A (vIL-10) results in down
regulation of MHC class II and diminished CD4+ T cell
recognition [49] and latent infection of CD34+ bone marrow
progenitor cells induces release of cIL-10 and TGFb which
decreases CD4+ T cell IFNc production and cytotoxicity [14]. We
have not been able to determine if LUNA protein expression in
latently infected cells can be recognized by LUNA specific T cells
and thus this remains an open question.
The results presented here now demonstrate that both UL138
and LUNA-specific CD4+ T cells also, themselves, secrete the
immunomodulatory cytokine cIL-10, in direct contrast to CD4+ T
cells specific for gB and IE antigens (which are expressed solely
during lytic infection). Interestingly, our analysis of the latency-
associated antigens US28 and UL111A also showed a skewing of
T cell responses towards CD4+ T cells which secreted cIL-10
suggesting that immune evasion during latency is a complex
interplay between the microenvironment around the latently
infected cell and the properties of the immune cells recruited to it.
In the donors analysed directly ex vivo, there was a clear bias
towards CD4+ T cells which secreted cIL-10 in response to the
latency associated HCMV gene products UL138, LUNA,
UL111A and US28. Not all donors respond to every latency
associated gene product, however, when all four antigens (UL138,
LUNA, US28 and UL111a) were taken together for the 13 donors
tested two donors made no responses, one donor made an IFNã
response and the remaining 10 donors had an cIL-10 response to
at least one of the latently expressed antigens. Indeed, if a donor
did not make a T cell response to any latently expressed antigen
there is no requirement for cIL-10 producing latent antigen
specific T cells. Regarding the single donor we found that makes
an IFNã response but no associated cIL-10 response to latent
antigens it is possible that there are other latent antigens that have
yet to be recognised. We have recently published that UL144 is
also expressed during latency [57] and it is possible that this donor
makes cIL-10 to this antigen. Alternatively, it is possible that some
donors do make antiviral responses to latent antigens that are not
balanced with a cIL-10 T cell response and that these individuals
may turn out to have lower latent viral loads than individuals with
higher frequency cIL-10 responses.
Interestingly, EBV also induces high frequencies of CD4+ T
cells specific to latent antigens; targeting EBNA1 which suppress
the proliferation and cytokine production of both CD4+ and CD8+
T cells [58] and LMP1 that also secrete cIL-10 [37–39]. cIL-10
secreting CD4+ T cells are known to perform an immunomod-
ulatory role in the immune response, often functioning to restrict
immune activation [59–61] and are a classical signature of Treg
cells [40,59]. It was interesting to note that the UL138 and LUNA
T cell lines expanded in vitro more slowly than the gB specific T cell
lines (data not shown). We were also able to show that the
suppression of polyclonally activated CD4+ T cell proliferation was
due to cIL-10 and TGFb secreted in the supernatant from UL138
specific T cells. In MCMV latency, cIL-10 producing CD4+ T
cells have been isolated from salivary glands. Furthermore, in cIL-
10 knockout mice (or after IL-10R blockade) the latent MCMV
load is reduced [62] with a concomitant increase in memory
MCMV-specific T cell frequency being observed. These observa-
tions are consistent with the view that cytomegalovirus may induce
cIL-10 producing CD4+ T cells to prevent latently infected cells
from being recognised by the immune system [63].
In contrast to EBV, it was not known whether viral gene
products expressed during HCMV latency generate Treg cells.
Lytic HCMV (IE and pp65) antigen specific Treg cells have been
described, particularly enriched in kidney transplantation patients
that had recurring HCMV reactivation events. The authors
suggested that frequent episodes of antigen stimulation might drive
the Treg phenotype and they further demonstrate that the antigen
specific Treg cells had the same TCR as effector T cells, suggesting
a common lineage [41]. IE and pp65 specific Treg cells were also
isolated from normal healthy donors but at lower frequencies than
in recurrent patient groups. In this study we examined IE and gB
specific CD4+ T cells and in some healthy individuals we were able
to identify cIL-10 producing cells in addition to predominant IFNc
secreting cells, which is in agreement with the Schwele observa-
tions. However, key to this study, is the detection of cIL-10
production by UL138 and LUNA specific CD4+ T cells in a larger
number of donors than was seen with IE and gB specific CD4+ T
cells. Indeed, the number of donors that had cIL-10 secreting T
cells specific for US28 and UL111A was striking and within
individual donors was often dominant over IFNc producing T cells
of the same specificity.
It is unclear why CD4+ T cell responses to HCMV lytic antigens
appear to be dominated by IFNc producing cells, while CD4+ T
cells, which recognise antigens, expressed during latent infection
predominantly secrete cIL-10. Many factors are likely to impact
upon the type of CD4+ T cell response generated to a particular
antigen, and this is known to include the cytokines present in the
microenvironment during T cell activation. During latent infec-
tion, viral gene expression in CD34+ cells is highly restricted and
associated with secretion of immunomodulatory cytokines cIL-10
and TGFb [14]. This immunosuppressive microenvironment may
Figure 7. Supernatant from PBMC stimulated with UL138 suppresses CD4+ T cell proliferation. PBMC were stimulated with either UL138
or gB peptides for 48 hours and the supernatant harvested. PBMC were labelled with a fluorescent dye and were cultured in the presence of the
supernatant from the PBMC stimulated with UL138 or gB, or alternatively media (control). PBMC were then stimulated or remained unstimulated
(Negative) with anti-CD3/CD28 beads for 5 days and where then stained with anti-CD3 and anti-CD4 antibodies, dead cells excluded by the use of 7-
amino-actinomycin D. Cells were gated according to (A) and the proliferation of CD4+ T cells was analysed by flow cytometry (B). The same analysis
was performed on three individual donors (C). Error bars are standard error of the mean (n = 3). Statistical analysis was performed using the students t
test (p,0.01). The same analysis was performed on PBMC from four separate donors and prior to the addition of PBMC supernatants were treated
with neutralising anti-IL-10 and/or anti-TGFb antibodies or isotype control antibodies and proliferation assays performed and analysed as previously
(D). Error bars are standard error of the mean (n = 4). Statistical analysis was performed using the students t test (* p,0.05; ** p,0.01).
doi:10.1371/journal.ppat.1003635.g007
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Figure 8. A subset of UL138 specific CD4+ T cells express phenotypic hallmarks of Treg cells. CD4+ T cells specific to UL138 (A) or gB (B)
from 3 donors were expanded in vitro for 14 days and then stained for stable surface expression of CD25 (C). Numbers in the top right quadrant
represent percentage of CD4+ CD25hi cells (A and B). Error bars represent standard error of the mean (n = 3); Statistical analysis was performed using
the students t test (C). PBMC were stained directly ex vivo for surface expression of CD25 and intracellular expression of FoxP3 or using an isotype
control (D). Quadrant numbers represent percentage of CD4+ cells. In vitro expanded cells from two donors, specific to UL138 and gB (CMV305) or
UL138, LUNA and gB (CMV300) were stained for expression of CD4, CD25 and FoxP3 (E). CD4+ CD25hi cells were analysed for expression of FoxP3.
doi:10.1371/journal.ppat.1003635.g008
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Figure 9. UL138, LUNA, US28 and UL111A specific cells secrete IL-10 and IFNc directly ex vivo. PBMC from 13 HCMV seropositive donors
were prepared and used in parallel ELISPOT assays detecting IFNc (black), IL-10 (white), IL-4 (blue) and IL-17 (red). PBMC were stimulated with PHA (A)
or peptide pools spanning HCMV open reading frames IE, gB, UL138, LUNA, US28 or UL111A (B). Post incubation spot forming units (SFU) were
enumerated for each cytokine response and the proportion of the total T cell response calculated as a percentage. All samples performed in triplicate,
data shown is the mean (Error bars not shown).
doi:10.1371/journal.ppat.1003635.g009
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also have an impact on the generation of CD4+ T cells activated
during latent phases of infection. Specifically, the CD34+ mediated
secretion of cIL-10 and TGFb, may result in the generation of cIL-
10 producing, immunomodulatory CD4+ T cells specific to latent
antigens but not those expressed solely during lytic infection [64–
67]. It is highly plausible that these effects act in concert with the
known functions of latency-associated UL111A (vIL-10) which has
been shown to promote MHC class II down-regulation and inhibit
CD4+ T cell activation [29–31,49] as well as restrict the ability of
latently infected myeloid cells to differentiate. This ability to
modulate the ability of the infected cell to function as a
professional antigen presenting cell as has been seen during
HSV infection of plasmacytoid DCs [68,69].
It has been shown that that some HCMV seropositive donors
generate cIL-10 secreting T cells to lytic HCMV antigens (such as
pp65) [41], in agreement with these observations we have also seen
cIL-10 producing T cells specific for gB and IE in a small number of
donors tested. Schwele et al clearly demonstrated that these cIL-10
producing T cells were generated at a higher frequency in
reactivating transplant individuals (speculated to be due to repeated
antigenic stimulations) and, as our cohort were normal healthy
donors, this probably accounted for the lower frequency of
detection in our analysis. It might be expected that in older HCMV
seropositive donors, who have carried the virus for many years, that
you would see the generation of cIL-10 producing CD4+ T cells to
lytic antigens and maybe an increase in frequency to latent antigens.
Our data highlights the consistent generation of cIL-10 producing
CD4+ T cells, in most normal healthy donors, to antigens expressed
in latency and thus the possibility that this is important in preventing
the immune clearance of latently infected cells.
We believe that there are potential clinical implication from
these findings, in the case of bone marrow transplantation (D+/
R2) if it were possible to eliminate or drastically reduce the latent
viral load prior to transplantation this could either prevent
reactivation or substantially reduce reactivation loads. We
speculate that since the T cell response to the latent antigens is
composed of both anti-viral (Th1) and immunesuppressive
activities the neutralization of cIL-10/TGFb may allow Th1 type
latent specific T cells to recognize and results in the elimination of
latent CD34+ cells.
In conclusion, based on this and other studies we suggest that a
number of direct and indirect immune suppressive mechanisms
may act together to help maintain sites of HCMV latency: Virally
encoded UL111A (vIL-10) expressed during latency down
regulates MHC class II expression on APCs restricting T cell
recognition of latently infected cells [49]; latent infection of CD34+
cells results in increases in cIL-10 and TGFb in the cell secretome,
which act to suppress antiviral immune responses in the
microenvironment of latently infected cells [14] and now we
show that CD4+ T cells specific for viral latency-associated gene
products, themselves secrete cIL-10 which helps suppress antiviral
effector functions. This biasing of the immune response by latency-
associated antigens, to elicit CD4+ T cells that secrete cIL-10, may
assist in the maintenance of the latent reservoir and lifelong
carriage of HCMV in vivo.
Materials and Methods
Ethics statement
Ethical permission for this project was granted by the
Cambridgeshire 2 Research Ethics Committee (REC reference
97/092). Informed written consent was obtained from all of the
volunteers included in this study prior to providing blood samples.
Identification of donor HCMV serostatus
HCMV serostatus of 23 healthy volunteers was determined
using a commercial HCMV specific IgG ELISA kit (Captia,
Trinity biotech, Ireland). The assay was performed according to
manufacturer’s instructions.
Human leukocyte antigen typing of donors
Human leukocyte antigen typing was performed for donors
regardless of HCMV serostatus. All MHC class I alleles (HLA-A,
HLA-B, HLA-C) and HLA-DR and HLA-DQ MHC class II
alleles were typed by molecular methods by Helen Stevens
(Cambridge Institute for Medical Research, UK) (Table S1).
Peptide libraries
Sequences for viral proteins from the clinical HCMV strain
Merlin were used and peptides constructed as sequential 15 amino
acid peptides with 10 amino acid overlap, spanning UL138 (Table
S2A), LUNA (Table S2B), US28 (Table S2C) and UL111A (Table
S2D) gB, IE and pp65 from Proimmune (UK). Peptides were
reconstituted and stored according to manufacturer’s instructions
to give a storage concentration of 40 mg/ml. Individual peptides
were further diluted in RPMI 1640 (PAA laboratories, Austria) to
create a stock of 1 mg/ml and a working concentration of each
peptide of 40 mg/ml and stored at 280uC. Peptide pools were
made for screening purposes from the single peptides, and were
constructed to give 2 mg/ml of each individual peptide. These
peptide pools were then stored in 100 ml aliquots at 280uC.
Preparation of peripheral blood mononuclear cells
(PBMC)
Venous blood was collected in heparin sodium (100 IU/ml),
diluted 1:2 with RPMI-1640 containing no serum (PAA labora-
tories, Austria) supplemented with 100,000 IU/ml penicillin,
100 mg/ml streptomycin, and 2 mmol/ml L-glutamine (RPMI-
wash). Peripheral blood mononuclear cells (PBMC) were isolated
by Lymphoprep (Axis-Shield, Norway) centrifuged at 800 g for
15 minutes. Autologous serum was removed from the interface
and incubated at 60uC for 30 minutes in a water bath to inactivate
complement.
Transformation of donor derived lymphoblastic B cell
lines
LCL lines were established according to published protocols
[70].
Detection of cytokine production by ELISPOT assays
ELISPOT plates were prepared, coated and blocked according
to manufacturer’s instruction (EBioscience). PBMC directly ex vivo,
previously frozen, or depleted of either CD4+ or CD8+ T cells by
magnetic activated cell sorting (MACS), were plated 3.06105 cells
in 100 ml RPMI-10 per well (of a 96 well Multiscreen IP sterile
plate (Millipore, UK)). Plates were incubated for 48 hours at 37uC
5% CO2, and developed according to manufacturer’s instruction.
Plates were read using an ELISPOT plate scanner (ELISPOT
Reader System, AID) and spots enumerated using ImageJ
(National Institutes of Health).
Depletion of CD4+ or CD8+ T cells from PBMC
PBMC were depleted of either CD4+ or CD8+ T cells by MACS
using either anti-CD4+ or anti-CD8+ direct beads (Miltenyi, U.K.),
according to manufacturer’s instructions and separated on LS columns
(Miltenyi, U.K.). Efficiency of depletion was determined by staining
cells with either anti-CD4 or anti-CD8 antibodies and analysed by flow
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cytometry. Depletions performed in this manner resulted in 0.1–0.8%
CD4+ cells and 0.3–0.8% CD8+ cells, respectively.
In-vitro expansion of antigen specific CD4+ T cells
CD4+ T cells were purified by MACS using anti-CD4 direct
beads (Miltenyi, UK) and separated on LS columns (Miltneyi, UK)
according to manufacturer’s instructions which resulted in CD3+
CD4+ mean cells purities of 98.1% (range 95.6–99.8%) as
determined by flow cytometry. PBMC (5.06106) were incubated
with 100 ml of the peptide of interest (2 mg/ml) for two hours at
37uC before irradiation using a sealed source irradiator for
30 minutes. These cells were then washed in PBS, resuspended in
RPMI-1640 supplemented with 10% autologous donor serum,
100,000 IU/ml penicillin, 100 mg/ml streptomycin, and 2 mmol/
ml L-glutamine. PBMC were then transferred 5.0610
5 cells per well
of a 96 well round bottomed microtitre plate. MACS purified CD4+
T cells were then added 1.06104 cells per well and incubated at
37uC for 14 days. RPMI-1640 supplemented with 10% autologous
donor serum, 100,000 IU/ml penicillin, 100 mg/ml streptomycin,
and 2 mmol/ml L-glutamine and 15 IU/ml recombinant IL-2
(National Institute of Biological Standards and Control, U.K) was
added 50 ml per well on days 2, 8 and 12 of culture.
Detection and quantification of cytokine production by
multi-cytokine assay
The production of cytokines by peptide specific T cell lines was
determined using Flowcytomix Th1/Th2 11plex kit, or using
simplex kits for specific cytokines (Bendermed systems, Nether-
lands) according to manufacturer’s instructions. Samples were
analysed using a BD FACSort and data analysed using
Flowcytomix pro software (Bendermed systems, Netherlands).
Detection of TGFb production by ELISA
Supernatants from peptide stimulated CD4+ T cells were
assayed for the presence of TGFb by ELISA, according to
manufacturer’s instructions (R&D systems, U.K.).
Intracellular detection of cytokine production by flow
cytometry
PBMC were washed in PBS and 1.56106 cells were resuspended
in 500 ul RPMI-1640 supplemented with 10% autologous donor
serum, 100,000 IU/ml penicillin, 100 mg/ml streptomycin, and
2 mmol/ml L-glutamine, in polypropylene FACS tubes (B.D.,
U.K.). Cells were then incubated with 100 ml (40 mg/ml) of the
peptide of interest and incubated for 16 hours at 37uC +5% CO2.
Post incubation Brefeldin A and Monensin (Biolegend, U.K.) were
added to the cultures according to the manufacturers instructions,
and the tubes incubated for a further 4 hours. Post incubation cells
were stained with a LIVE/DEAD fixable dead cell stain kit
(Invitrogen, U.K.), according to manufacturers instructions. Cells
were then surface stained with anti-CD3 PE-Cy7 (B.D., U.K.) and
anti-CD4 PerCP Cy5.5 (B.D., U.K.) monoclonal antibodies
according to manufacturers instructions. Intracellular cytokines
were fixed and permeablised using the FoxP3/Transcription factor
staining buffer set (EBioscience, U.K.). Intracellular cytokines were
stained using anti-IFNc alexafluor 488 (Biolegend, U.K.) and anti-
IL10 PE (Biolegend, U.K.) and acquired using the FACS Canto II
(B.D., U.K.) and analysed using FlowJo software (Treestar, U.S.A).
Flow cytometric detection of Treg cells
Expanded T cell lines or PBMC were assayed for the presence
of Treg using the Human Regulatory T cell staining kit
(EBioscience, U.K.), according to manufacturer’s instructions.
T cell cytotoxicity assays
Cultured peptide specific T cell lines were used in a standard
Cr51-release assay against both HLA matched and mis-matched B
cell lines as target cells as previously described [70].
T cell suppression assays
PBMC were labelled with cell trace violet proliferation kit for
flow cytometry (Life technologies, U.K.), according to manufac-
turer’s instructions. Cells were then resuspended in RPMI-1640
supplemented with 10% autologous donor serum, 100,000 IU/ml
penicillin, 100 mg/ml streptomycin, and 2 mmol/ml L-glutamine.
Alternatively, PBMC were resuspended in supernatant from
PBMC cultures stimulated for 48 hours with gB or UL138
peptides, and plated 1.06105 per well of a round bottom 96 well
plate and incubated for 1 hour at 37uC +5% CO2. For
neutralisation assays, supernatants were treated with neutralising
antibodies for cIL-10, TGFb or both, or with the relevant isotype
control antibodies at a final concentration of 20 ng/ml for one
hour prior to the addition of the violet labelled PBMC. Post
incubation cells were stimulated with DynabeadsH Human T-
Activator CD3/CD28 (Life technologies, U.K.) at a bead to cell
ratio of 1:200. Alternatively cells remained unstimulated and all
wells were adjusted to a total volume of 200 ml and incubated for 5
days at 37uC +5% CO2. Post incubated cells were harvested and
washed in PBS prior to staining with anti-CD3 PE-Cy7 (B.D.,
U.K.) and anti-CD4 FITC (B.D., U.K.) antibodies. Cells were
then stained with 7-amino- Actinomycin D (Calbiochem, U.K.).
Cells were then washed in PBS and resuspended in FACS buffer
and acquired on the FACS Canto II and analysed FlowJo
software.
Generation of lytically infected dendritic cells
Monocytes were isolated from PBMC using anti-CD14 MACs
beads according to the manufactures instructions (Miltneyi, UK).
The purity of isolated monocytes was determined by flowcyto-
metric detection of CD14+ cells, resulting in mean CD14+
populations of 98.1% (range 97.4–98.9%, n = 5). Purified
monocytes were adhered to tissue culture plates overnight in
X-vivo15, medium was then changed to X-vivo15 supplemented
with 2.5 mM L-glutamine, 500 IU/ml IL-4 (Peprotech, UK) and
1000 IU/ml granulocte-macrophage colony stimulating factor
(GM-CSF) (Peprotech, UK) and incubated for a further 3 days at
37uC + 5% CO2. Post incubation cells were washed in PBS and
fresh X-vivo15 supplemented with 2.5 mM L-glutamine,
500 IU/ml IL-4 (Peprotech, UK) and 1000 IU/ml GM-CSF
(Peprotech, UK) was added for a further 3 days. Post incubation,
the cells were washed in PBS and matured by the addition of
1 ml X-vivo15 per well supplemented with 2.5 mM L-glutamine
and 50 ng/ml LPS for 48 hours. Cell surface phenotype of
monocytes and the iDC and mDC cells derived from them was
determined by flow cytometry using anti-CD14, CD80, CD86
and HLA-DR, as expected iDC and mDC lost CD14 and gained
CD83 expression, MHC Class II, CD80 and CD86 were all
upregulated (Figure S1). In vitro differentiated monocyte derived
dendritic cells were infected at MOI 5 for 3 hours at 37uC + 5%
CO2 in X-vivo15 supplemented with 2.5 mM L-glutamine. Post
incubation supernatant was removed and 1 ml X-vivo15
supplemented with 2.5 mM L-glutamine added per well and
further incubated at 37uC + 5% CO2. Media was changed every
3 days post infection and cells used as antigen presenting cells 5
days post infection in the presence or absence of cognate peptide.
Infection was confirmed by immunofluorescence and RT-PCR
(see below).
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Generation of latently infected monocytes
Monocytes were isolated from PBMC using anti-CD14 MACs
beads according to the manufactures instructions (Miltneyi, UK)
and adhered in tissue culture plates overnight in X-vivo15
supplemented with 2.5 mM L-glutamine overnight at 37uC +
5% CO2. Post incubation cells were washed in PBS and infected
with TB40e UL32GFP at an MOI of 5 for 3 hours at 37uC + 5%
CO2. Post incubation cells were washed in PBS and 1 ml fresh X-
vivo15 supplemented with 2.5 mM L-glutamine added and
incubated 37uC + 5% CO2 for 10 days. Medium was changed
every 3 days post infection and cells used as antigen presenting
cells 10 days post infection in the presence or absence of peptide.
Establishment of latency was confirmed at day ten by RT-PCR.
Immunofluorescence IE staining
Cells were fixed in 4% PFA in PBS for 10 minutes at room
temperature, washed twice in PBS prior to the addition of 0.1%
Triton-X in PBS for ten minutes at room temperature. 300 ml
mouse anti-IE antibody (1:1000; Millipore, UK) per well for
1 hour at room temperature, followed by PBS washes and then
stained with anti-mouse Alexafluor 594 (1:1000; Invitrogen, UK)
and DAPI (1:100; Invitrogen, UK) in 300 ml PBS for 1 hour at
room temperature in the dark. After washing cells were analysed
immediately by fluorescent microscopy.
RT-PCR of viral transcripts
RNA was extracted from in vitro cell infections using a previously
published method [71]. Briefly, adherent cells were washed in
chilled PBS and 1 ml TRIZOL (Invitrogen, UK) added per well (for
a maximum of 16106 cells), adherent cells were removed using a
cell scraper. RNA samples were DNase treated using the RQ1
RNase free DNase kit (Promega, UK) according to manufacturer’s
instructions. Samples were then reversed transcribed using the
Reverse transcription system (Promega, UK) according to manu-
facturer’s instructions. PCR was performed to amplify a range of
viral transcripts associated with either lytic or latent infection, or
cellular genes: GAPDH forward GAGTCAACG-
GATTTGGTCGT and GAPDH reverse TTGATTTTGGAGG-
GATCTCG [72]; IE forward GGACCCTGTAATCCTGACG
and IE reverse ATCTTTCTCGGGGTTCTCGT [73]; UL138
forward TGCGCATGTTTCTGAGCTC and UL138 reverse
ACGGGTTTCACAGATCGAC [28]; LUNA forward AT-
GACCTCTCCTCCACACC and LUNA reverse GGAAAAA-
CACGCGCGGGGGA [27] (all primers obtained from Sigma-
Adlrich, UK). 45 cycle PCR Biomix red (Bioline, UK), was
performed using: 95uC 1 minute, 55uC 40 seconds, 72uC 1 minute.
Supporting Information
Figure S1 Differentiation and phenotype of monocytes
and monocyte derived dendritic cells. Monocytes were
prepared from PBMC by CD14 selection and cultured in vitro.
Alternatively, monocytes were differentiated using IL-4 and GM-
CSF to immature dendritic cells (iDC) and then activated with
lipopolysaccharide to mature dendritic cells (mDC). All three cell
types were then stained with monoclonal antibodies specific for
CD14, CD83, HLA DR, CD86 and CD80 to determine their
phenotype by flow cytometry.
(TIF)
Figure S2 CD4+ T cell detection of lytic infection in
monocyte derived dendritic cells. Dendritic cells (A, C and
E) or Macrophaages (B, D and F) were prepared from donor
CMV305 and mock infected or lytically infected with TB40e for 5
days at MOI 5. Lytic infection was then confirmed by RT-PCR
(G). Autologous mock or TB40e infected dendritic cells or
monocytes were then co-incubated with in vitro expanded antigen
specific CD4+ T cells specific to gB, IE or UL138 in IFNc
ELISPOT assays in the presence or absence of cognate peptide
(A–F). Post incubation IFNc spot forming units (SFU/106) were
enumerated and the back ground level of IFNc production for
each antigen specificity determined from the mock infected no
peptide control (Red dotted line).
(TIF)
Figure S3 UL138 specific CD4+ T cells secrete IFNc in
response to latently infected monocytes. Monocytes were
prepared from donor CMV300 and mock infected or latently
infected with TB40e for 10 days at MOI 5. Latent infection was
then confirmed by RT-PCR (A). Autologous mock or latently
infected monocytes were then co-incubated with in vitro expanded
antigen specific CD4+ T cells specific to gB (B) and UL138 (C) in
IFNc ELISPOT assays in the presence or absence of cognate
peptide. Post incubation IFNc spot forming units (SFU/106) were
enumerated and the back ground level of IFNc production for
each antigen specificity determined from the mock infected no
peptide control (Red dotted line). Error bars are standard error of
the mean (n = 5). Statistical analysis were performed using the
students t test (* p,0.05;** p,0.01).
(TIF)
Figure S4 The UL138 specific T cell response is
composed of separate populations of IFNc and cIL-10
producing CD4+ T cells. PBMC from three seropositive donors
were stimulated with a range of peptides: CMV300 gB, UL138
and LUNA; CMV305 gB and UL138; CMV317 UL138 and
LUNA, and intracellular IFNc and cIL-10 were detected by flow
cytometry gating on the live CD3+ CD4+ lymphocyte population
(A). Quadrant values represent % of the total CD3+ CD4+
population for the Unstimulated (US) stimulated sample. Values
for the US were used to determine background cytokine secretion
and subtracted for sample stimulated with peptide. The proportion
of the responding population was then plotted for the percentage
of the total cytokine positive response for each donor and peptide
stimulation: IFNc+IL102 (White); IFNc+IL-10+ (Grey) and
IFNc-IL-10+ (Black) (B). UL138 and gB specific CD4+ T cells
from donor CMV305 were expanded in vitro for 14 days and then
stimulated with peptide prior to intracellular detection of IFNc
and cIL-10 by flowcytometric methods and analysis of the live
CD3+ CD4+ lymphocyte population (C). Background cytokine
production for each line was determined by an unstimulated
control (No peptide). Quadrant values show the percentage of the
live CD3+ CD4+ lymphocyte population for each condition.
(TIF)
Figure S5 Quantification of the T cell response to IE,
gB, UL138, LUNA, US28 and UL111A by multiple
cytokine specific ELISPOT assay. PBMC from 13 seropos-
itive donors were stimulated with overlapping peptide pools
spanning the HCMV open reading frames IE, gB, UL138, LUNA,
US28 and UL111A in separate ELISPOT assays detecting IFNc,
IL-10, IL-4 and IL-17. Post incubation assays were developed and
spot forming units (SFU) for each cytokine enumerated using
ImageJ. Background levels of cytokine production from each
donor were determined from an unstimulated control, subtracted
from the corresponding cytokine specific assay prior to conversion
to SFU/106 cells. Finally, values for each individual cytokine were
used to calculate a cumulative cytokine response (including all four
cytokines). Error bars represent standard error of the mean (n = 3).
(TIF)
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Table S1 Serostatus and HLA type of the cohort. All
donors were serologically type for HCMV IgG by ELISA (+)
HCMV seropositive (2) HCMV seronegative. All donors were
also HLA typed for HLA-A, B, C and HLA-DR and DQ by
molecular methods. (*) Unable to type further.
(DOCX)
Table S2 Peptide sequences of individual 15 amino acid
peptides of UL138 and LUNA. 32 overlapping 15mer peptides
of UL138 (A) and 20 overlapping 15mer peptides of LUNA (B)
and (C) 35 overlapping 15mer peptides of UL111A and (D) 69
overlapping 15mer peptides of US28.
(DOCX)
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